SEHK:2696Biotechs
A Look at Shanghai Henlius Biotech’s (SEHK:2696) Valuation Following Its Strategic Immunotherapy Partnership
Shanghai Henlius Biotech (SEHK:2696) has entered a strategic partnership with Forlong Biotechnology to jointly develop next-generation cancer immunotherapies. This move brings together Henlius’s antibody expertise and Forlong’s engineered cytokine technologies, further expanding Henlius’s oncology pipeline.
See our latest analysis for Shanghai Henlius Biotech.
Shanghai Henlius Biotech’s latest partnership news comes at a time when its stock has seen remarkable momentum, with the 1-year total...